| Document Date: 2014-11-03 11:26:22
Open Document File Size: 15,20 KBShare Result on Facebook
City Osaka / / Company Shionogi & Co. Ltd. / Launch Shionogi & Co. Ltd. / BioCryst Pharmaceuticals Inc. / Corporate Communications Department Shionogi & Co. Ltd. / / Country Taiwan / Korea / Japan / United States / / Currency JPY / / Event FDA Phase / / / IndustryTerm treatment of infectious diseases / manufacturing approval / manufacturing system / foreign healthcare reforms / with respect to product / / MedicalCondition H1N1 influenza / adult uncomplicated seasonal influenza infection / seasonal influenza virus infection / infectious diseases / Infection / severe and life-threatening influenza / uncomplicated seasonal influenza / influenza A / Influenza / / Person Isao Teshirogi / / / Position President / / Product RAPIACTA / NHI drug / /
SocialTag |
January 26, 2010 Shionogi & Co., Ltd. A Novel Anti-viral Drug for Influenza, “RAPIACTA 300mg Bag for Intravenous Drip Infusion” and “RAPIACTA 150mg Vial for Intravenous Drip Infusion” Launch